Journal article
In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses
D Jenika, S Pounraj, D Wibowo, LM Flaxl, BHA Rehm, JD Mintern
Npj Vaccines | NATURE PORTFOLIO | Published : 2024
Abstract
There is an unmet need for antigen delivery systems that elicit efficient T cell priming to prevent infectious diseases or for treatment of cancers. Here, we explored the immunogenic potential of biologically assembled biopolymer particles (BPs) that have been bioengineered to display the antigenic MHC I and MHC II epitopes of model antigen ovalbumin (OVA). Purified dendritic cells (DCs) captured BP-OVA and presented the associated antigenic epitopes to CD4+ T cells and CD8+ T cells. Vaccination with BP-OVA in the absence of adjuvant elicited antigen presentation to OVA-specific CD8+ and CD4+ T cells and cross-primed effective cytotoxic T lymphocyte (CTL) killers. BP-OVA induction of CTL kil..
View full abstractRelated Projects (2)
Grants
Awarded by Tour de Cure
Funding Acknowledgements
This work was supported by grants from National Health and Medical Research Grants. 1161101 (J.D.M.) and 1129672 (J.D.M.) and Australia Research Council Grants 190101242 (J.D.M.), 180100844 (J.D.M.), 160101373 (J.D.M.), 180100521 (J.D.M.). B.H.A.R. acknowledges the support. from the Australian Research Council (ARC) Discovery Projects (DP200100874 and DP220102236), ARC Linkage Infrastructure, Equipment and Facilities (LE20010014) and Tour de Cure. The authors acknowledge technical assistance by Yaoying Lu (Griffith University) and the facilities, and the scientific and technical assistance, of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy and Microanalysis at the University of Queensland.